DrugPatentWatch Database Preview
NATPARA Drug Profile
» See Plans and Pricing
Summary for Tradename: NATPARA
| Patents: | 1051 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for NATPARA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NATPARA |
Recent Clinical Trials for NATPARA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Entera Bio Ltd. | Phase 2 |
| Shire | Phase 1 |
| University of Bergen | Phase 0 |
Recent Litigation for NATPARA
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Ravgen, Inc. v. Progenity, Inc. | 2020-12-20 |
| Juul Labs Inc v. EZfumes | 2020-07-10 |
| Genentech, Inc. v. Samsung Bioepis Co. Ltd. | 2020-06-28 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| 2018-07-13 | |
| 2017-07-28 | |
| Pfizer, Inc. | 2017-05-19 |
Pharmacology for NATPARA
| Ingredient-type | Parathyroid Hormone |
Company Disclosures: US Patents for NATPARA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 001 | 2015-01-23 | Start Trial | Allelix BioPharmaceuticals Inc. (Ontario, CA) | 2039-03-29 | RX | Orphan | company |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 002 | 2015-01-23 | Start Trial | Allelix BioPharmaceuticals Inc. (Ontario, CA) | 2039-03-29 | RX | Orphan | company |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 003 | 2015-01-23 | Start Trial | Allelix BioPharmaceuticals Inc. (Ontario, CA) | 2039-03-29 | RX | Orphan | company |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 004 | 2015-01-23 | Start Trial | Allelix BioPharmaceuticals Inc. (Ontario, CA) | 2039-03-29 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for NATPARA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 001 | 2015-01-23 | Start Trial | ASAHI KASEI PHARMA CORPORATION (Tokyo, JP) | 2031-06-07 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 001 | 2015-01-23 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 001 | 2015-01-23 | Start Trial | Novartis AG (Basel, CH) | 2032-03-30 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 001 | 2015-01-23 | Start Trial | ASCENDIS PHARMA A/S (Hellrup, DK) | 2024-07-05 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 001 | 2015-01-23 | Start Trial | Immunomedics, Inc. (Morris Plains, NJ) | 2033-02-15 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for NATPARA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2374042 | Start Trial |
| Canada | 2279331 | Start Trial |
| Bulgaria | 101813 | Start Trial |
| Japan | 2014159441 | Start Trial |
| Spain | 2741524 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NATPARA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| CA 2005 00027 | Denmark | Start Trial | PRODUCT NAME: CINACALCET ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER HYDROCHLORIDET |
| C00911342/01 | Switzerland | Start Trial | PRODUCT NAME: DENOSUMABUM; REGISTRATION NO/DATE: SWISSMEDIC 60210 03.08.2010 |
| 91759 | Luxembourg | Start Trial | 91759, EXPIRES: 20230415 |
| C300741 | Netherlands | Start Trial | PRODUCT NAME: CICLOSPORINE (EYE DROP; REGISTRATION NO/DATE: EU/1/15/990 20150319 |
| 1090038-9.L | Sweden | Start Trial | PRODUCT NAME: DENOSUMAB; REG. NO/DATE: EU/1/10/618/001 20100526 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
